SILVER SPRING, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that world renowned oncologist and gastroenterologist Professor Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, has agreed to play a major role in Nuvilex’s Phase 2b clinical trial in pancreatic cancer to be conducted in Australia, as well as other clinical studies and trials in which Nuvilex will be involved. Dr. Löhr served as Principal Investigator for the previous Phase 1/2 clinical trials that employed Nuvilex’s pancreatic cancer treatment.
Help employers find you! Check out all the jobs and post your resume.
